Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
暂无分享,去创建一个
R. Tibshirani | S. Fröhling | J. Pollack | E. Bair | L. Bullinger | K. Döhner | R. Schlenk | H. Döhner
[1] J. Rowley,et al. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML‐2 cell line , 1996, Genes, chromosomes & cancer.
[2] U. Thorsteinsdóttir,et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia , 1997, Molecular and cellular biology.
[3] M. Caligiuri,et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. , 1998, Cancer research.
[4] C. Bloomfield,et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.
[5] Unnur Thorsteinsdottir,et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.
[6] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[7] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. Meijer,et al. The role of Homeobox genes in normal hematopoiesis and hematological malignancies , 1999, Leukemia.
[9] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[10] Joshua M. Stuart,et al. MICROARRAY EXPERIMENTS : APPLICATION TO SPORULATION TIME SERIES , 1999 .
[11] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[12] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[13] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. Bloomfield,et al. Clinical importance of cytogenetics in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.
[16] B. Löwenberg. Prognostic factors in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.
[17] T. Yamagata,et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. , 2001, Blood.
[18] 水野 晋一,et al. Expression of DNA methyltransferases DNMT1,3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia , 2001 .
[19] M. Caligiuri,et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[21] S. Fröhling,et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[23] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[24] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[25] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[26] S. Soker,et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.
[27] S. Fröhling,et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[29] D. Botstein,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[30] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[31] R. Eils,et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[33] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[35] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[36] C. Galmarini,et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia , 2002, British journal of haematology.
[37] D. Gilliland,et al. Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.
[38] B. Burgering,et al. Cell cycle and death control: long live Forkheads. , 2002, Trends in biochemical sciences.
[39] E. Lander,et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.
[40] N. Ferrara,et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.
[41] E. Lander,et al. A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.
[42] Chi Wai So,et al. Common mechanism for oncogenic activation of MLL by forkhead family proteins. , 2003, Blood.
[43] David Botstein,et al. The Stanford Microarray Database: data access and quality assessment tools , 2003, Nucleic Acids Res..